In this study, we synthesized a series of phenylpropanoic acid derivatives based on modifications at four selected points of the molecular scaffold. The in vitro antiproliferative activities of the compounds were examined in representative human solid tumor cell lines. A SAR was established pointing out the relevance of the substituents. The best activity profiles were obtained for the derivatives bearing more lipophilic esters (GI 50 3.1-21 µM).
Phenylpropanoic acids such as caffeic, ferulic, and cinnamic acids, together with their analogues (1-7) are widely distributed in nature. Previous studies have shown that some caffeic acid derivatives possess a wide range of biological activities, including anticancer 0, antibacterial 0, antioxidant 0, and antiviral 0. Caffeic acid phenyl ethyl ester (CAPE, 3), first isolated from beeswax in 1988, was proved to have remarkable cytotoxicity in tumor and virally transformed cells, but not in normal cells 0. Furthermore, 3 is a constituent of natural honey-propolis and demonstrated strong antitumor effects in oral cancer cells. Despite the reports on anticancer activities of 3 and its derivatives, little is known about their mechanism of action.
For years, cancer researchers have been trying to find a way to target chemotherapeutic agents more precisely, to deliver the agents not only to that part of the body affected by a cancer, but to the internal areas of the tumor. In this context, an important point of attention is the development of new approaches to facilitate the uptake of chemotherapeutic agents into cancer cells. The cell membrane that surrounds each cell is a highly lipophilic structure and represents the ultimate drug penetration barrier. Among the proposed methods to enhance the passive internalization of drugs into cells, increasing their lipophilicity has often been demonstrated as a successful way. Some cytotoxic agents have been improved via these so-called prodrug approaches 0. The traditional approach to increase drug lipophilicity consists in the introduction of long aliphatic chains, generally in the form of fatty acid esters or phosphate esters 0. Lipophilicity of antitumor drugs also can be increased by the addition of low molecular weight fragments, either at the main backbone or blocking polar functional groups. In this particular context, we reported earlier the enhancement of cytotoxicity in tert-butyldimethylsilyl (TBS) containing compounds with respect to their parent derivatives 0.
In this work we report the antiproliferative activities of a small set of more lipophilic caffeic (5) , ferulic (6) and cinnamic (7) acid derivatives. In order to perform structure-activity relationship (SAR) studies, we envisioned four possible points of modification of the molecular scaffold (Table 1) : the ester residue (Z), the α,β-unsaturated carbonyl group (X), and the para (R) and meta (R') substituents on the aromatic ring.
The preparation of caffeic acid derivatives was carried out as shown in Figure 1 . Ester derivatives were obtained by means of conventional esterification methods reported in the literature and were chosen in order to optimize yields (see Experimental). Briefly, ester 8 was obtained by reacting 5 with CH 2 N 2 in diethyl ether; ester 11 was prepared by activation with dicyclohexylcarbodiimide (DCC); esters 14 and 15 were prepared by Fischer esterification using the corresponding alcohol; ester 13 was obtained by activation with chlorotrimethylsilane in ethanol 0; and finally, ester 17 was prepared by treatment with methyl sulfate in acetone 0. Acetylated derivatives in the aromatic ring 9, 12 and 16 were prepared under typical acetylation conditions from alcohols 8, 11 and 5, respectively 0. Saturated derivatives 10 and 19 were obtained by hydrogenation using Pd on charcoal as catalyst and EtOAc as solvent. Finally, saponification of 17 under alkaline conditions led to 18.
The preparation of ferulic and cinnamic acid derivatives was carried out as shown in Figure 2 . Compounds 20 and 22 were obtained by catalytic hydrogenation of ferulic (6) and cinnamic (7) acids, respectively. Esters 21, 23, and 24 were prepared by treating 6, 7, and 22 with CH 2 N 2 in diethyl ether, respectively.
Figure 1:
Reagents and conditions: a) CH 2 N 2 , Et 2 O, 81%; b) Ac 2 O, DMAP, Py, 85% for 9, 76% for 12, 78% for 16; c) H 2 , Pd/C, 1 atm, AcOEt, 75% for 10, 88% for 19; d) DCC, DMAP, n-heptanol, 66%; e) (CH 3 ) 3 SiCl, EtOH, 93%; f) HCl, i-PrOH, 60%; g) HCl, n-PrOH, 72%; h) Me 2 SO 4 , K 2 CO 3 , NaF, acetone, 78%; i) KOH, H 2 O, 54%. that should be globally associated with drug solubility and drug permeability through cell membranes 0. The octanol/water partition coefficient (K ow ) is widely used to express the lipophilicity of drugs. K ow corresponds to the ratio of a compound's concentration in octanol to its concentration in water when both phases reach the equilibrium. Because the values of K ow can range over many orders of magnitude, it is commonly expressed in logarithmic form (log K ow or log P). Partition coefficients can be determined either experimentally or calculated. The latter are called ClogP (calculated log P) or MlogP (Moriguchi log P) if the Hansch-Leo's fragment constant method 0 or Moriguchi's method 0 are used, respectively. However, ClogP values are more accurate than MlogP values. There exist several computer programs that calculate the ClogP values 0, with ClogP® the more accurate predictor and the one chosen for our study 0.
The ClogP values for compounds 5-24 were in the range 0.64 to 4.38 and are given in Table 1 . ClogP values were calculated to correlate lipophilicity with the biological activity. Overall, a direct correlation between lipophilicity of the side chain (Z) and antiproliferative activity was obtained.
The in vitro antiproliferative activity of compounds 5-24 was evaluated using the National Cancer Institute (NCI) protocol 0 after 48 h of drug exposure using the sulforhodamine B (SRB) assay 0. The results expressed as 50% growth inhibition (GI 50 ) are shown in Table 1 . From the GI 50 values, some structure-activity relationships can be inferred, as follows. When comparing the three parental drugs 5-7, caffeic acid (5) was the only compound to inhibit cell growth in the most sensitive cell lines HBL-100 and SW1573, with GI 50 values of 49 and 35 µM, respectively. This trend was observed for the three families. Thus, caffeic acid derivatives were more active than the corresponding ferulic and cinnamic series. With the exception of caffeic acid (5) , all derivatives bearing carboxylic acids were inactive (GI 50 > 100 µM) against all cell lines. The most active compounds of the series were analogs 11 and 12, which showed GI 50 values in the range 3.1-21 µM.
From the aforementioned four intervention points in the molecular scaffold, the most relevant for activity was the side chain ester (Z). In this particular feature, a direct relationship between lipophilicity and activity was obtained. This observation is more evident for the more resistant cell lines T-47D and WiDr. The order of activity was established n-Hep > n-Pr ≈ i-Pr ≈ Et > Me. The α,β-unsaturated group, although not essential in the case of HBL-100, HeLa and SW1573 cells, contributes positively to the biological activity (8 > 10), as shown with T-47D and WiDr cells. The replacement of the aromatic hydroxyl groups for methoxy groups produces a decrease in activity or even inactivation of the compound (5 > 6, 8 > 21 > 17). From the data, it appears that a m-OH group is more relevant for activity than the p-OH (8 > 21 > 17). However, the acetylation of the hydroxyl groups does not produce a significant change in activity (8 ≈ 9, 11 ≈ 12, 5 >= 16).
In summary, we have synthesized a small subset of phenylpropionic acid derivatives paying attention to four structural moieties in the general scaffold. The analysis of the antiproliferative activity in human solid tumor cell lines gave a SAR, pointing out some tips for further development of new analogs. Although preliminary, the 
Experimental
General procedure: Caffeic acid (5), ferulic acid (6), cinnamic acid (7), dimethylaminopyridine (DMAP), potassium carboxide and methyl iodide were purchased from the Aldrich Chemical Company. 1,3-Dicyclohexylcarbodiimide (DCC) and sodium sulfate hydrate were purchased from the Sigma-Aldrich Chemical Company. Synthesized products were purified on a silica gel column and identified by TLC, NMR, IR and GC/Mass analysis. NMR spectra were recorded on a Bruker-Advance 200 spectrometer. Mass spectra (MS) were recorded on a Finnigan-Mat-GCQ-plus mass spectrometer. TLC was performed on precoated silical gel F254 plates (Merck) using a 254 nm UV lamp to monitor these reactions.
(E)-Methyl 3-(3,4-dihydroxyphenyl)acrylate (8):
To a stirred solution of caffeic acid (5) (100 mg, 0.56 mmol) in anhydrous diethyl ether (50 mL) at 0ºC was added, dropwise, a solution of diazomethane in diethyl ether. The reaction was monitored by TLC. After completion, the reaction mixture was removed from the ice bath and left 30 min at room temperature. After this time, the solvent was removed under reduced pressure. The resulting residue was purified by silica gel CC using n-hexane: EtOAc 
Preparation of (E)-4-(3-methoxy-3-oxoprop-1-enyl)-1,2-phenylene diacetate (9):
To a stirred solution of 8 (100 mg, 0.52 mmol) in dry pyridine (1.03 mL) at room temperature were sequentially added acetic anhydride (131.4 mg, 1.3 mmol) and 4dimethylaminopyridine (6.3 mg, 0.05 mmol). The reaction mixture was left with stirring overnight, protected from light, and monitored by TLC. When the reaction was completed, 20 mL of ice-cold distilled water and 20 mL of diethyl ether were added. The organic phase was washed with 5% copper sulfate (3 x 20 mL) and water (2 x 20 mL). The organic fraction was dried over anhydrous Na 2 SO 4 . The solvent was removed under reduced pressure. The resulting residue was purified by CC on silica gel using n-hexane: EtOAc (7:3) as eluent. We obtained 122 mg of 9 as yellow oil. Yield: 85%. 
Preparation of methyl 3-(3,4-dihydroxyphenyl)-propanoate (10):
Pd/C (22 mg) was added in one portion to a solution of 9 (200 mg, 1.03 mmol) in EtOAc (50 mL). The mixture was stirred under a hydrogen atmosphere for 2 h. Then, the catalyst was removed by filtration and washed with ethyl acetate. The solvent was evaporated under reduced pressure and the residue purified by flash chromatography on silica gel, using n-hexane: EtOAc (7:3). 158 mg of 10 was obtained as yellow oil. Yield: 75%.
Preparation of (E)-heptyl 3-(3,4-dihydroxyphenyl)-acrylate (11):
To a stirred solution of 5 (200 mg, 1.12 mmol) in dichloromethane (30 mL) were added dicyclohexylcarbodiimide (347 mg, 1.68 mmol) and 4-dimethylaminopyridine (205 mg, 1.68 mmol). The mixture was stirred for 30 min and then 1-heptanol (156.6 mg, 190.5 μl, 1.34 mmol) was added. The reaction mixture was filtered through celite to remove the dicyclohexylurea generated. The organic layer was washed twice with 10% HCl to remove the base and then once with water, dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by flash chromatography using 60G Sigel and n-hexane: EtOAc 
Preparation of (E)-4-(3-(heptyloxy)-3-oxoprop-1-enyl)-1,2phenylene diacetate (12):
To a stirred solution of 11 (150 mg, 0.54 mmol) in dry pyridine (1.08 mL) was added acetic anhydride (137.5 mg, 1.35 mmol) and 4-dimethylaminopyridine (6.59 mg, 0.05 mmol). The reaction mixture was left with stirring overnight, protected from light, and monitored by TLC. When the reaction was complete, 20 mL of cold distilled water and 20 mL of diethyl ether were added. The organic phase was washed with 5% copper sulfate (3 x 20 mL) and water (2 x 20 mL). The organic fraction was dried with anhydrous Na 2 SO 4 , and the solvent removed under reduced pressure. The resulting residue was purified by CC on silica gel using n-hexane: EtOAc 
Preparation of (E)-ethyl 3-(3,4-dihydroxyphenyl)-acrylate (13):
To a stirred solution of 5 (100 mg, 0.56 mmol) in dry ethanol (5 mL) at room temperature was added, dropwise, trimethylchlorosilane (0.11 ml, 0.79 mmol). The reaction mixture was stirred overnight. After completion, as monitored by TLC, the solvent was removed under reduced pressure. The resulting residue was purified by CC on silica gel using n-hexane: EtOAc (7:3) as eluent to give 107.96 mg of 13 as yellow oil. Yield: 93%. 
Preparation of (E)-isopropyl 3-(3,4-dihydroxyphenyl)-acrylate (14):
To a stirred solution of 5 (200 mg, 1.12 mmol) in isopropyl alcohol (30 mL) was added concentrated HCl (0.5 mL, 37%, v/v). The reaction mixture was stirred for 3 h at reflux temperature. The excess alcohol was removed under reduced pressure, and the residue taken up with water and extracted with diethyl ether (3 x 15 mL). The organic layer was washed with bicarbonate solution (pH = 9.7), followed by distilled water, and dried over anhydrous Na 2 SO 4 . The solvent was removed under reduced pressure, and purified by CC on silica gel using n-hexane: EtOAc 
Preparation of (E)-propyl 3-(3,4-dihydroxyphenyl)-acrylate (15):
To a stirred solution of 5 (200 mg, 1.12 mmol) in n-propyl alcohol (50 mL) was added concentrated HCl (0.5 mL, 37%, v/v). The reaction mixture was stirred for 3 h at reflux temperature. The excess alcohol was removed under reduced pressure, and the residue taken up with water and extracted with diethyl ether (3 x 15 mL). The organic layer was washed with bicarbonate solution (pH = 9.7), followed by distilled water, and dried with anhydrous Na 2 SO 4 . The solvent was removed under reduced pressure, and purified by CC on silica gel using n-hexane: EtOAc 
Preparation of (E)-3-(3,4-diacetoxyphenyl)acrylic acid (16):
To a stirred solution of 5 (100 mg, 0.56 mmol) in dry pyridine (1.2 mL) were added acetic anhydride (2.7 mL, 1.4 mmol) and 4-dimethyl-aminopyridine (6.8 mg, 0.056 mmol). The reaction mixture was left with stirring overnight, protected from light, and monitored by TLC. When the reaction was complete, 20 mL of cold distilled water and 20 mL of diethyl ether were added. The organic phase was washed with copper sulfate 5% (3 x 20 mL) and water (2 x 20 mL). The organic fraction was dried with anhydrous sulfate, filtered, and the solvent removed under reduced pressure. The resulting residue was purified by CC on silica gel using n-hexane: EtOAc (7:3) as eluent; 115 mg of 16 was obtained as yellow oil. Yield: 78%. 1 H NMR: In full agreement with the literature 0. Anal. Calcd for C 13 
Preparation of (E)-methyl 3-(3,4-dimethoxyphenyl)-acrylate (17):
A stirred solution of 5 (200 mg, 1.12 mmol), K 2 CO 3 (1.6 g, 11.7 mmol), and NaF (0.49 g, 11.7 mmol) in acetone (10 mL) was heated until reflux. Then, methyl sulfate (1.26 g, 9.9 mmol) was added dropwise. After 2 h the reaction was complete (controlled by TLC). The reaction mixture was cooled and filtered through celite. The organic phase was washed with a saturated solution of NaHCO 3 , and then dried with anhydrous Na 2 SO 4 , filtered and concentrated; 192 mg of 17 was obtained as yellow oil. Yield: 78%. 
Preparation of (E)-3-(3,4-dimethoxyphenyl)acrylic acid (18):
To a stirred solution of 17 (100 mg, 0.45 mmol) in EtOAc (5 mL) was added a solution of KOH (25.2 mg, 0.45 mmol) in distilled water (30 mL). The mixture was refluxed until completion, as monitored by TLC. The solution was acidified with HCl (5% in water). The mixture was extracted with diethyl ether (3 x 20 mL), dried with Na 2 SO 4 , filtered, and concentrated on a rotary evaporator. The residue was purified by silica gel CC using n-hexane: EtOAc (7:3) to obtain 50.6 mg of 18 as yellow oil. Yield: 54%. 1 
Preparation of 3-(3,4-dihydroxyphenyl)propanoic acid (19):
Pd/C (22 mg) was added in one portion to a solution of 5 (200 mg, 1.12 mmol) in EtOAc (50 mL). The mixture was stirred under hydrogen for 2 h and the catalyst removed by filtration and washed with ethyl acetate. The solvent was evaporated under reduced pressure and the residue purified by flash chromatography on silica gel using n-hexane: EtOAc (7:3) to give 177.35 mg of 19. Yield: 88%. 1 H NMR (400 MHz, CDCl 3 ): 2.72 (2H, t, J = 8 Hz, H-8), 3.00 (2H, t, J = 8 Hz, H-7); 7.33-7.24 (5H, m). 13 Reta et al. based on the difference in OD at the start (T 0 ) and end of drug exposure (T), according to the National Cancer Institute (USA) formulas 0. Therefore, if T is greater than or equal to T 0 the calculation is PG = 100  [(T-T 0 )/(C-T 0 )]. If T is less than T 0 denoting cell killing the calculation is PG = 100  [(T-T 0 )/(T 0 )]. With these calculations, 3 levels of effect could be determined; 50% growth inhibition (GI 50 ), total growth inhibition (TGI), and 50% cell killing (LC 50 ) that represent the concentration at which PG is +50, 0, and -50, respectively. Thus, a PG value of 0 corresponds to the amount of cells present at the start of drug exposure, while negative PG values denote net cell kill.
